MétaCan
Menu
Back to cohort
Record W2613856979 · doi:10.1093/ntr/ntx097

Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

2017· review· en· W2613856979 on OpenAlexafffund
Li‐Shiun Chen, Laurie Zawertailo, Thomas M. Piasecki, Jaakko Kaprio, Marilyn G. Foreman, Hannah R. Elliott, Sean P. David, Andrew W. Bergen, James W. Baurley, Rachel F. Tyndale, Timothy B. Baker, Laura J. Bierut, Nancy L. Saccone

Bibliographic record

VenueNicotine & Tobacco Research · 2017
Typereview
Languageen
FieldMedicine
TopicSmoking Behavior and Cessation
Canadian institutionsUniversity of TorontoCentre for Addiction and Mental Health
FundersNational Institute on Minority Health and Health DisparitiesNational Institute on Alcohol Abuse and AlcoholismNational Cancer InstituteNational Institute on Deafness and Other Communication DisordersNational Institute on Drug AbuseNational Heart, Lung, and Blood InstituteMedical Research CouncilCanadian Institutes of Health ResearchOak FoundationAcademy of FinlandUniversity of BristolEconomic and Social Research CouncilCanadian Cancer Society
KeywordsPrecision medicineSmoking cessationGenotypingPersonalized medicineData collectionClinical trialPharmacotherapyNicotineMEDLINEMedicineNicotine dependenceMedical physicsData sciencePsychologyComputer scienceBioinformaticsPsychiatryInternal medicineStatisticsBiologyGenotypeGeneticsPathology

Abstract

fetched live from OpenAlex

In an era of Precision Medicine, it is vital to collect biological data within clinical trials and to integrate their analysis within the outcomes of the trial. The identification of genomic biomarkers that affect treatment response to smoking cessation treatment, both pharmacological and behavioral, or susceptibility to medication-related adverse reactions, holds real promise to improve treatment efficacy and to tailor the treatment approach to the individual. However, a clear challenge in identifying reliable biomarkers is in obtaining adequate sample sizes. Consortium-based approaches will likely be necessary to yield real successes. Thus, meta-analyses of data from individual smoking cessation trials will become crucial and will be facilitated by standardized trial designs, assessments, and outcomes and harmonizable measures. To foster increased collection of high-quality genetics data in clinical trials, we discuss (1) genetically informed trial design, (2) biological samples (collection requirements, storage, and analysis with a focus on genomic data) and genetics consortia, (3) participant consent and data sharing requirements for Institutional Review Board (IRB) approvals, and (4) information on phenotype characterization and meta-analysis. This work aligns with the objectives of the Precision Medicine Initiative and offers guidance for integrating treatment research and genetics/genomics within the nicotine and tobacco research community. It is intended to promote the collection and genotyping of biosamples in existing subject samples as well as the integration of genetic research elements into future study designs. This article cross-references a companion paper in this issue that reviews current evidence on genetic and epigenetic markers in cessation trials. This article outlines a framework for the consistent integration of biological data/samples into smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled Precision Medicine Initiative. Our goal is to encourage and provide support for treatment researchers to consider biosample collection and genotyping their existing samples as well as integrating genetic analyses into their study design in order to realize precision medicine in treatment of nicotine dependence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.387
metaresearch head score (Gemma)0.581
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.387
Threshold uncertainty score0.756

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3870.581
Meta-epidemiology (narrow)0.0030.003
Meta-epidemiology (broad)0.0080.008
Bibliometrics0.0070.008
Science and technology studies0.0030.023
Scholarly communication0.0260.041
Open science0.0070.009
Research integrity0.0190.023
Insufficient payload (model declined to judge)0.0060.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.607
GPT teacher head0.546
Teacher spread0.061 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations19
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueNicotine & Tobacco ResearchSame topicSmoking Behavior and CessationFrench-language works237,207